Last reviewed · How we verify

ACE-536 — Competitive Intelligence Brief

ACE-536 (ACE-536) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Activin receptor ligand trap. Area: Hematology.

phase 3 Activin receptor ligand trap Activin type II receptor Hematology Biologic Live · refreshed every 30 min

Target snapshot

ACE-536 (ACE-536) — Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA. ACE-536 is an activin receptor ligand trap that inhibits activin signaling to promote erythropoiesis and increase hemoglobin levels.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ACE-536 TARGET ACE-536 Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA phase 3 Activin receptor ligand trap Activin type II receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Activin receptor ligand trap class)

  1. Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA · 1 drug in this class
  2. Celgene · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ACE-536 — Competitive Intelligence Brief. https://druglandscape.com/ci/ace-536. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: